Bayer to pay US$14.2bn for Merck & Co's OTC

6 May 2014 - Deborah Wilkes

Archived

Bayer has agreed to acquire US-based Merck & Co's Consumer Care business for US$14.2 billion in cash. In addition to a portfolio of strong OTC brands – led by the allergy remedy Claritin (loratadine) – the deal includes the global trademark and prescription rights to Claritin and the nasal decongestant Afrin (oxymetazoline).

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: